Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Design of the Reversal Effects of Idarucizumab on Active Dabigatran... | Download Scientific Diagram
These highlights do not include all the information needed to use PRAXBIND safely and effectively. See full prescribing information for PRAXBIND. PRAXBIND® (idarucizumab) injection, for intravenous useInitial U.S. Approval: 2015
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment | Journal of the American College of Cardiology
Usefulness of initial plasma dabigatran concentration to predict rebound after reversal | Haematologica
Clinical Effectiveness of Idarucizumab in Dabigatran Reversal | Wang | Journal of Cardiology and Therapy
Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French phar
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination - Stephan Glund, Guanfa Gan, Viktoria Moschetti, Paul Reilly, Markus Honickel, Oliver Grottke, Joanne Van Ryn,
Clinical Evidence | Praxbind® (idarucizumab)
Idarucizumab for Reversal of Dabigatran – Core EM
Idarucizumab (PRAXBIND) | STROKE MANUAL
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols - ScienceDirect
Idarucizumab (PRAXBIND) | STROKE MANUAL
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study | SpringerLink
Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant - Labiotech.eu
Idarucizumab | Circulation
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Idarucizumab, the Sequel – Emergency Medicine Literature of Note
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Ef
Idarucizumab for Dabigatran Reversal – The Bottom Line
